Lancashire and South Cumbria
Formulary
Formulary
13 Skin
This chapter of the formulary is under continual development, please let the team know if you have any comments about the contents: mlcsu.lscformulary@nhs.net.
For more information about the formulary development process, please see: https://www.lancsmmg.nhs.uk/lancashire-and-south-cumbria-icb-formulary-development/
13-11-06 Oxidisers, and dyes
| Potassium Permanganate Permitabs® |
|
Formulary
|
Solution tablets 400mg Primary Care : Potassium permanganate should always be prescribed for a named patient by a primary care prescriber, experienced in the treatment of dermatological conditions and use of potassium permanganate.
Secondary Care:- Potassium permanganate concentrate should always be prescribed for a named patient by a specialist in dermatology, a clinician working under the guidance of a dermatologist, or specialist tissue viability staff only.
Note: A risk assessment must be completed if potassium permanganate is to be used in a patient's home
|
 BAD and NHS England & NHS Improvement guidance on the safe use of potassium permanganate soaks NHS Central alerting system |
|
Links
- BAD and NHS England & NHS Improvement guidance on the safe use of potassium permanganate soaks
- BAD and NHS England & NHS Improvement guidance on the safe use of potassium permanganate soaks
LSCMMG: Gastroenterology Biologics Pathway- LSCMMG: Primary Care Constipation Guidelines
- MHRA alert: Risk of gas embolism when used in surgery
- NaPSA - Inadvertent oral administration of potassium permanganate April 2022
- NHS Central alerting system
- NHS England: Patient safety alert Dec 2014
- NICE CG147: Diverticular disease: diagnosis and management
- NICE CG184 Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management
- NICE CG61: Irritable bowel syndrome in adults: diagnosis and management
- NICE NG1: Gastro-oesophageal reflux disease: recognition, diagnosis and management in children and young people